These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25690270)

  • 1. Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.
    Lee JH; Jeong SK; Kim BC; Park KW; Dash A
    Acta Neurol Scand; 2015 May; 131(5):259-67. PubMed ID: 25690270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology.
    Sabbagh M; Cummings J
    BMC Neurol; 2011 Feb; 11():21. PubMed ID: 21299848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
    Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
    Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
    Homma A; Atarashi H; Kubota N; Nakai K; Takase T
    J Alzheimers Dis; 2016 Mar; 52(1):345-57. PubMed ID: 26967222
    [TBL] [